The purpose of this study is to assess adherence, tolerability and satisfaction of each eligible HIV subjects switching from a two- or three-pill tenofovir-emtricitabine-efavirenz (TDF-FTC-EFV) to a one-pill TDF-FTC-EFV treatment.
Each eligible patient will be screened from de SHCS database. Each refusal and drop-out will be documented. A pre-visit (V-1) will be scheduled for informed consent, V0 for inclusion (V-1 and V0 may occur on the same day), V1 one month post-inclusion and V2 4 to 7 months post-inclusion. V0, V1 and V2 will be planned during regular medical visits. Eligible patients either get their cART in their usual pharmacy according to standard of care, or take part in a routine adherence-enhancing program(adherence subgroup)run by the pharmacists of the outpatient medical clinic. In the adherence subgroup, adherence is assessed electronically by MEMS (Medication event monitoring system) monitors on a regular basis.
Study Type
OBSERVATIONAL
Enrollment
95
Centre Hospitalier Universitaire Vaudois et Policlinique Medicale Universitaire
Lausanne, Canton of Vaud, Switzerland
Patient adherence
by questionnaire in both subgroups and by MEMS data in the adherence subgroup
Time frame: V0, V1, V2
Adverse events and symptoms
by questionnaires
Time frame: V0, V1, V2
Treatment management
Treatment management according to meals, timing, disruptive daily schedule By questionnaire
Time frame: V0, V1, V2
Patient satisfaction of the switch
By questionnaire
Time frame: V1, V2
Impact of switch on clinical outcomes
Clincal outcomes = viral load, CD4 count, resistance, EFV blood level. By medical file
Time frame: V0, V1, V2
Patients' acceptance of switch
Time frame: V-1
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.